BioCentury
ARTICLE | Clinical News

Z160: Phase IIa started

January 7, 2013 8:00 AM UTC

Zalicus began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 375 mg oral Z160 twice daily for 6 weeks in about 140 patients with chronic neuropathic pain associated with PHN. This trial is the second of 2 Phase IIa trials of Z160 to treat chronic neuropathic pain. In September, Zalicus began a double-blind, placebo-controlled, U.S. Phase IIa trial in 140 patients with lumbosacral radiculopathy (see BioCentury, Sept. 10, 2012). Data from both trials are expected late in 2H13. ...